News › Clinical Practice, Industry News, Patient Care

Melanoma Study Suggests Altered Schedule

June 27, 2018

Recent melanoma research has shown that altering drug administ­ration can improve the outcome. Andre Aplin, PhD, associate director for Basic Research and the program leader for Cancer Cell Biology and Signaling (CCBS), and Jessica Teh, PhD, his senior postdoctoral researcher at Jefferson University, conducted research to examine the impact of two FDA-approved targeted agents, MEK and CDK4/6, on human melanomas that have been grafted onto mice. This research was published in Cancer Discovery, and it showed that changing the schedules of drug administ­ration can improve outcomes.
Read More at Skin Inc >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Estée Lauder Executive’s Death Linked to Pulmonary Embolism Following Cosmetic Filler Injection
    • Allergan Aesthetics Receives Approval for Boey® (trenibotulinumtoxinE) in Canada
    • SafeLink Consulting Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • Allergan Aesthetics’ Skinvive by Juvéderm Receives FDA Approval for the Improvement of Neck Appearance
    • Obagi Medical Announces FDA Approval of Obagi saypha ChIQ Injectable Hyaluronic Acid Gel